Nektar Therapeutics released positive maintenance data from the 52‑week Phase IIb REZOLVE‑AD study of rezpegaldesleukin (rezpeg) in moderate‑to‑severe atopic dermatitis. The drug hit high rates of EASI‑75 and EASI‑90 responses in maintenance cohorts and showed large patient‑reported improvements in itch, the company said in trial disclosures and an investor note covered by market press. Management disclosed an FDA‑agreed induction regimen and plans to start Phase‑3 later this year; Nektar concurrently closed a $460 million underwritten offering to fund the development program and commercial preparedness. Chief R&D officer Jonathan Zalevsky characterized the results as a “comeback story,” noting durable responses with monthly and quarterly maintenance dosing. Rezpeg is an IL‑2 receptor‑targeting biologic designed to expand regulatory T cells; the program’s next steps include pivotal design finalization with regulatory agencies and larger safety datasets to support a BLA in the 2029 timeframe the company has cited.